Zura Bio (NASDAQ:ZURA) Shares Up 12.5% - Here's Why

Zura Bio Limited (NASDAQ:ZURA - Get Free Report)'s stock price traded up 12.5% on Wednesday . The stock traded as high as $1.45 and last traded at $1.35. 2,013,427 shares changed hands during trading, an increase of 327% from the average session volume of 472,034 shares. The stock had previously closed at $1.20.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Oppenheimer decreased their target price on Zura Bio from $19.00 to $17.00 and set an "outperform" rating for the company in a research note on Friday, May 9th. Chardan Capital decreased their target price on Zura Bio from $12.00 to $10.00 and set a "buy" rating for the company in a research note on Wednesday, March 26th. Guggenheim restated a "buy" rating and set a $15.00 target price on shares of Zura Bio in a research note on Wednesday, March 26th. Finally, HC Wainwright reaffirmed a "buy" rating on shares of Zura Bio in a report on Thursday, April 3rd. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Zura Bio currently has an average rating of "Buy" and an average price target of $14.33.

Zura Bio Trading Down 5.8%

The firm has a fifty day simple moving average of $1.15 and a 200 day simple moving average of $1.41. The stock has a market cap of $89.57 million, a price-to-earnings ratio of -1.87 and a beta of -0.10.

Zura Bio (NASDAQ:ZURA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.02). On average, equities analysts expect that Zura Bio Limited will post -0.65 earnings per share for the current year.

Institutional Investors Weigh In On Zura Bio

Several large investors have recently modified their holdings of ZURA. American Century Companies Inc. bought a new stake in shares of Zura Bio in the 4th quarter valued at approximately $27,000. Prudential Financial Inc. bought a new stake in shares of Zura Bio in the 4th quarter valued at approximately $28,000. Two Sigma Advisers LP bought a new stake in shares of Zura Bio in the 4th quarter valued at approximately $32,000. ProShare Advisors LLC bought a new stake in shares of Zura Bio in the 4th quarter valued at approximately $35,000. Finally, XTX Topco Ltd bought a new stake in shares of Zura Bio in the 4th quarter valued at approximately $44,000. 61.14% of the stock is currently owned by institutional investors.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.